Fig. 7: Dasatinib greatly reduced tumor growth. | Cell Death & Differentiation

Fig. 7: Dasatinib greatly reduced tumor growth.

From: Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation

Fig. 7

a Dasatinib treatment significantly reduced tumor growth. We isolated JCRB1033 cells according to cell-surface EGFR expression using a FACSAria sorter, and then each cell population was subcutaneously injected into the left flank of different BALB/c nude mice. For these experiments, the mice were treated as follows: cetuximab or IgG, 5 mg/kg intravenously twice per week; dasatinib, 10 mg/kg by oral gavage 2 days a week for 4 weeks. *p < 0.01 vs. vehicle. Representative images of Ki-67 (b) and TUNEL staining (c) in tumor xenografts sections. Scale bars in (b) 50 μm; in (c) 100 μm. d Immunohistochemical staining of EGFR pTyr1148 and Src pTyr416 in tumor xenografts sections. Scale bars: 50 μm.

Back to article page